HEICO Contingent consideration fair value adjustments decreased by 43.6% to $2.23M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 32.3%, from $3.29M to $2.23M. Over 3 years (FY 2021 to FY 2025), Contingent consideration fair value adjustments shows an upward trend with a 114.7% CAGR.
Increases often signal that acquired assets are performing better than expected, requiring higher future payouts, while decreases may suggest lower-than-anticipated success in R&D milestones.
This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past bu...
Standard for R&D-heavy firms that frequently acquire biotech companies with milestone-based deal structures.
operating_business_combination_contingent_consideration__7f0be7| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $227.00K | $646.00K | $0.00 | -$114.00K | -$1.66M | -$2.48M | -$3.38M | $1.34M | $506.00K | -$624.00K | -$1.90M | $1.10M | -$6.42M | -$5.57M | $3.29M | $3.48M | $2.21M | $3.95M | $2.23M |
| QoQ Change | — | +184.6% | -100.0% | — | <-999% | -49.5% | -36.2% | +139.6% | -62.1% | -223.3% | -205.1% | +157.5% | -686.4% | +13.3% | +159.1% | +5.8% | -36.5% | +78.7% | -43.6% |
| YoY Change | — | — | — | — | -830.8% | -483.9% | — | >999% | +130.5% | +74.8% | +43.6% | -18.0% | <-999% | -792.0% | +200.3% | +154.2% | +139.7% | — | -32.3% |